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Abstract
Background: Surgeons have a range of materials to choose from to complete wound closure, yet surprisingly very
little is still known about the body’s immune response to the suture materials in current use. The growing literature
of adverse suture material reactions provided the objective of this study, to use in vitro assays to quantify levels of
inflammation produced by seven commonly used suture materials in surgical procedures.
Methods: Human monocyte/macrophage THP-1 cells were exposed to suture materials for 1, 3 and 5 days. Gene
expression and protein secretion of six inflammatory cytokines and two cell surface markers were assessed using
qPCR and ELISA respectively, with LPS exposure providing a positive control. Furthermore, a IL-1β/IL-1RA marker
ratio was assessed to determine the balance between pro-/anti-inflammatory expression.
Results: The findings from our in vitro study suggest that four commonly used suture materials cause upregulation of
pro-inflammatory markers indicative of an early foreign body reaction, with no balance from anti-inflammatory markers.
Conclusions: As prolonged early pro-inflammation is known to produce delayed wound healing responses, the
knowledge produced from this study has potential to improve informed surgical decision making and patient
safety. This work has the capability to reduce suture-related adverse immune reactions, and therefore positively
affect patient outcomes.
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Background
Surgeon’s have a wide range of suture materials to choose
from to complete wound closure. These are mostly syn-
thetic monofilament or polymeric sutures, which have
replaced traditional natural-based sutures due to the
natural sutures being associated with inflammation and
hypersensitivity reactions [1–4]. Most non-absorbable
sutures remain in situ for periods of at least 10 days,
while absorbable options remain for many months, yet
surprisingly little is known about the body’s immune
response to the suture materials in current use [5, 6].
There have been many published cases where foreign
body reactions to suture material have caused complications
and rejection post-surgery, both in the short and long-term.
Warme et al. (2004) reported the first case of a foreign body
reaction to Ticron® suture, with a resultant localised granu-
lomatous abscess requiring drainage and re-operation three-
years post-surgery [7]. Moreover, five cases of sinus forma-
tion and granulomatous reaction to FiberWire® suture have
been reported at sites of lower leg amputation [8]. These
suture related granulomas were discovered between 5–16
months post-surgery. To date, there have also been five
reported cases of suture-related pseudoinfection (SRPI) and
granuloma formation following wound closure with the
VICRYL® suture material, all less than ten weeks post total
hip arthroplasty. These cases all required debridement
and surgical revision [9, 10].
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All of these cases ruled out infection with negative cul-
ture, and attributed patient outcome solely to adverse
suture material reaction following histological examin-
ation of the inflammatory masses. However, the true scale
of the adverse suture material reaction is likely much
larger than what is available in the literature, as cases will
often go unreported.
The current literature is in substantial need of immune
response data for such a wide range of suture materials.
Given the global push for a reduction in animal studies
[11], in vitro studies offer a viable and ethical alternative
for obtaining this required data. However, such studies
have been few in number. One early published report
measured immune response in vitro using peritoneal
macrophages originally isolated from Wistar rats, and
showed significantly increased tumour necrosis factor
alpha (TNFα) production from cells exposed to Mersilk®,
PDS II® and VICRYL® sutures [12]. In a more recent study,
Musson et al. (2015) isolated primary human dendritic cells
to evaluate the immune response of silk-based tendon bio-
material scaffolds in vitro, and used the suture material
FibreWire® as a clinical control. This study used cytometric
bead array analysis to measure concentrations of multiple
pro-inflammatory cytokines in the cell conditioned media
and found that concentrations of interleukin-1 beta (IL-1β),
interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12
(IL-12) and TNFα were elevated in cells exposed to Fibre-
Wire®, compared to baseline negative control [13].
Here, we use in vitro assays to quantify levels of in-
flammation produced by seven common suture materials;
VICRYL®, MONOCRYL®, Ethilon®, Ti-Cron®, FibreWire®,
Perma-Hand® and Ethibond EXCEL®. Our aim is that the
information obtained from this study be provided to sur-




Seven suture materials (VICRYL®, MONOCRYL®, Ethilon®,
Perma-Hand®, Ethibond EXCEL®, (Ethicon Inc.®, New
Jersey, USA), Ti-Cron® (Covidien®, Dublin, Republic of
Ireland) and FiberWire® (Athrex®, Florida, USA)) were
sourced from our local hospital. Suture materials were
obtained pre-sterilised by gamma-irradiation and pack-
aged for clinical use. Respective sutures were cut into
homogenous 5mm sections, placed into 24-well tissue
culture plates, and pre-soaked in Roswell Park Memorial
Institute (RPMI) cell media (Invitrogen™, ThermoFisher
Scientific, Australia) for 24 hours. Sterile conditions were
maintained in class II laminar flow hoods.
THP-1 cell culture
Monocytic THP-1 cells were sourced from the American
Tissue Culture Collection (THP-1, TIB-202™, ATCC®).
Human monocyte/macrophage cell line THP-1 cells
were cultured in 75cm2 tissue culture flasks with 30mL
RPMI media supplemented with 10% fetal bovine serum
(FBS) (HyClone Laboratories, Utah, USA), 10,000U/mL
Penicillin/Streptomycin mixture (Gibco, ThermoFisher
Scientific Inc., Massachusetts, USA) and 1mM Sodium
Pyruvate. Cells were maintained at 37°C inside a humidi-
fied atmosphere of 5% CO2:95% air until the required
number of cells were present. The cells were collected in
50mL falcon tubes and centrifuged at 12000rpm for two
minutes. Cell pellets were then resuspended for a second
time in fresh RPMI media. Finally, a haemocytometer
was used to estimate cell number, and the cell suspen-
sion diluted in cell culture media to achieve a 1.5million
cells/mL concentration.
1.5 million THP-1 cells (1mL cell suspension) were
seeded onto each of the pre-prepared suture materials
inside 24-well tissue culture plates, as described above
(n = 4). Additional wells in the plates were allocated for
negative and positive controls (n = 4). The negative con-
trol wells consisted of 1.5 million THP-1 cells cultured
alone, whilst the positive control wells consisted of 1.5
million THP-1 cells treated with 5 ng/mL lipopolysac-
charide (LPS, Sigma-Aldrich NZ Ltd). Plates were incu-
bated at 37°C inside a humidified atmosphere of 5%
CO2:95% air. Culture time periods were 1, 3 and 5 days
post cell-seeding.
Gene expression analysis
RNA for real-time quantitative polymerase chain reaction
(qPCR) was prepared and combined from both adherent
and non-adherent THP-1 cells exposed to the suture
materials for 1, 3, and 5 days. Cells were lysed with β-
mercaptoethanol in RLT buffer (QIAGEN Pty Ltd, VIC,
Australia) and incubated at 55°C with 0.2mg/ml protein-
ase K (Invitrogen™, Life Technologies) for 15 minutes. 80%
v/v ethanol was added and RNA extracted using the
RNeasy mini kit (QIAGEN). Genomic DNA was removed
from all RNA preparations with the RNase-free DNase set
(QIAGEN). The quantity and purity of the RNA were
measured using a Nanodrop™ Lite Spectrophotometer
(Thermo-Scientific, Massachusetts, USA), with a 260/280
absorbance value of >1.8 being considered acceptable.
500ng RNA was used to make cDNA. cDNA was synthe-
sized with Superscript III (Invitrogen™, Life Technologies)
in the presence of an RNase inhibitor (RNaseOUT™,
Invitrogen™, Life Technologies) and used for quantita-
tive real-time polymerase chain reaction (qPCR), with a
Quantstudio™ 12K Flex Real-Time PCR System (Applied
Biosystems by Life Technologies). Primers and probe sets
were purchased as fluorescently labelled TaqMan® Gene
Expression Assays (Cat. # 4331182, Invitrogen™, Life
Technologies). All probes used to detect target genes
were labelled with FAM™ and the 18S rRNA endogenous
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control probe was labelled with VIC®. The ΔΔCt method
was used to calculate the relative levels of expression com-
pared to a control sample from day one [14]. All probes
used span exon-exon junctions thus do not detect gen-
omic DNA, and negative control (no cDNA) reactions
were also used for each of the TaqMan® assays, without
a positive signal.
Six inflammatory cytokines and two cell surface
markers genes were assayed. Interleukin-1 alpha (IL-
1α) (Hs00174092_m1), IL-1β (Hs00174097_m1), TNFα
(Hs01113624_g1) and interleukin-8 (IL-8) (Hs00174103_m1)
are pro-inflammatory cytokines produced by macrophages
of the M1 (classically activated) population [15–17]. C-C
chemokine receptor type 7 (CCR7) (Hs01013469_m1) is a
cell surface marker found on activated M1 macro-
phages [17]. Transforming growth factor beta (TGFβ1)
(Hs00998133_m1) and interleukin-1 receptor antagon-
ist (IL-1RA) (Hs00893626_m1) are anti-inflammatory
cytokines produced by macrophages of the M2 (alterna-
tively activated) population [15–17]. Cluster of differen-
tiation 163 (CD163) (Hs00174705_m1) is a cell surface
marker found on M2 macrophages [17].
Protein secretion analysis
IL-1β protein concentrations from the conditioned cell
media of THP-1 cells exposed to suture materials were
analysed using an R & D systems human IL-1β/IL-1F2
Duoset Enzyme-Linked Immunosorbent Assay (ELISA)
kit (Pharmaco NZ Ltd.). THP-1 cell-free media was
diluted out 1 in 2, and 1 in 4 per sample, using RPMI
media to allow comparisons to neat cell-free media.
100μl of each neat sample and respective dilutions were
used inside 96-well plates. Standard antibody was diluted
in 1% bovine serum albumin in phosphate buffered saline
(reagent diluent). Pure reagent diluent was used as a nega-
tive control. Plates were read on a Synergy 2 Plate Reader
(Biotek®, Vermont, USA) at 450nm absorbance. Final IL-
1β protein concentrations were determined in pg/ml.
Statistical analysis
Both gene expression and protein secretion analyses
were repeated twice to allow for technical variation, with
three independent biological experiments performed per
suture material. Data were analysed using two-way ana-
lysis of variance (ANOVA) with post hoc Dunnett’s test,




THP-1 cells were cultured with the chosen suture mate-
rials and harvested on days 1, 3 and 5. The relative gene
expression of six inflammatory cytokines and two cell
surface markers were measured by qPCR. The most rep-
resentative biological repeat is reported.
Pro-inflammatory markers
Relative gene expression of five pro-inflammatory
markers (four cytokines (IL-1β, IL-1α, TNFα and IL-8)
and one cell surface marker (CCR7) is shown in Fig. 1a.
The positive LPS control significantly upregulated all
pro-inflammatory markers, except for IL-1α and TNFα
on day 5.
The only suture that caused a statistically significant
IL-1β upregulation in the THP-1 cells was Perma-Hand®
on day 3 with an approximate 60-fold expression in-
crease compared to untreated cells (p < 0.05). Other not-
able IL-1β upregulation against negative control came
from cell exposed to Perma-Hand® on day 1, VICRYL®
on days 1 and 3, Ti-Cron® on days 3 and 5, and FibreWire®
on day 5, but these were not statistically significant. Cells
exposed to MONOCRYL®, Ethilon® and Ethibond EXCEL®
produced similar levels of IL-1β expression to negative
control over all time points.
IL-1α was expressed at the lowest levels of all pro-
inflammatory markers. No suture material caused sig-
nificant increases in IL-1α expression compared to the
control cells. Sutures caused varying levels of IL-1α up-
regulation, generally peaking on day 3. VICRYL®, Ti-
Cron® and Perma-Hand® did upregulate IL-1α expression
in cells on day 3, however, none of these were statisti-
cally significant. Again, cells exposed to MONOCRYL®
and Ethilon® produced similar levels of IL-1α expression
to negative control over all time points.
TNFα was the pro-inflammatory marker that was up-
regulated most by all sutures. Increases in expression
varied for sutures across the culture period, but all
peaked on day 3. Of all sutures, Ti-Cron® caused the
greatest increase in TNFα expression, with significant in-
creases of 3340-fold (p < 0.0001) and 920-fold (p < 0.01)
on days 3 and 5, respectively. FiberWire® also caused
significant increases, with 2600-fold (p < 0.0001) and
1940-fold (p < 0.0001) increases in expression seen on days
3 and 5, respectively. Ethibond EXCEL® also signifi-
cantly increased TNFα upregulation on day 3 with
1990-fold (p < 0.0001) expression. Cells exposed to
MONOCRYL® and Ethilon® produced similar levels of
TNFα expression to negative control over all time points.
The most significant upregulation of IL-8 expression,
compared to the negative control, came from exposure
to VICRYL® on day 3, with a 50-fold increase in relative
gene expression (p < 0.0001). The next highest was
Ti-Cron® on days 3 and 5 with 45-fold (p < 0.0001)
and 20-fold (p < 0.01) increases, respectively. Perma-Hand®
also significantly increased IL-8 expression in THP-1 cells
on day 3 with a 38-fold increase (p < 0.0001). Other notable
increases above baseline came from exposure to VICRYL®
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and Perma-Hand® on day 1, Ethibond EXCEL® on day 3,
and FiberWire® on day 5. However, these did not reach
statistical significance. Peak levels of IL-8 expression
came mostly on day 3. Once more, cells exposed to
MONOCRYL® and Ethilon® produced similar levels of
IL-8 expression to negative control over all time points.
Of all sutures, Perma-Hand® caused the greatest increase
in CCR7 expression in the THP-1 cells, compared to nega-
tive control, with a statistically significant 34-fold increase
seen on day 3 (p < 0.0001). VICRYL® also caused a signifi-
cant increase in CCR7 expression on this day with a 15-
fold increase (p < 0.05). At other time points, exposure to
these sutures, along with all others, resulted in expression
similar to or reduced from negative control.
Anti-inflammatory markers
Relative gene expression of three anti-inflammatory
markers (two cytokines (TGFβ1 and IL-1RA) and one
cell surface marker (CD163) is shown in Fig. 1b. The
positive LPS control produced statistically significant
increases in the expression of TGFβ1 on day 1, IL-
1RA on days 1 and 3, and CD163 on day 3.
TGFβ1 was expressed at the lowest levels for all anti-
inflammatory markers. Ti-Cron® caused the greatest in-
crease in TGFβ1 expression on day 3, with a significant
4.5-fold increase (p < 0.001). Exposure to all other su-
tures caused either similar or reduced levels of TGFβ1
expression in the THP-1 cells compared to negative con-
trol, over all days.
Fig. 1 a Gene Expression Results. Relative gene expression of five pro-inflammatory markers (four cytokines (IL-1β, IL-1α, TNFα and IL-8) and one
cell surface marker (CCR7)) from THP-1 cells in contact with a variety of suture materials were measured by RT-PCR on days 1, 3 and 5. The most
representative independent biological repeat is reported ± SEM. Statistical analysis was performed using two-way ANOVA and post-hoc Dunnett’s
test (*p < 0.05, **p < 0.01, ***p < 0.001), ****p < 0.0001). b Gene Expression Results. Relative gene expression of three anti-inflammatory markers
(two cytokines (TGFβ1 and IL-1RA) and one cell surface marker (CD163)) from THP-1 cells in contact with a variety of suture materials were measured
by RT-PCR on days 1, 3 and 5. The most representative independent biological repeat is reported ± SEM. Statistical analysis was performed
using two-way ANOVA and post-hoc Dunnett’s test (*p < 0.05, **p < 0.01, ***p < 0.001), ****p < 0.0001)
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All sutures caused a peak in IL-1RA expression levels
in the THP-1 cells on day 3. Of all sutures, Perma-
Hand® caused the greatest upregulation in IL-1RA ex-
pression, with a significant 12.5-fold increase on day 3
(p < 0.0001). THP-1 cells exposed to Ti-Cron® produced
the next highest, with a statistically significant 10.5-fold
increase when compared to the negative control cells on
day 3 (p < 0.0001). There were also significant increases
in IL-1RA expression on day 3 from cells exposed to
Ethilon® and Ethibond EXCEL® sutures, with both pro-
ducing approximately 7.5-fold increase (p < 0.05). Expos-
ure to all other sutures on this day, as well as all suture
materials on days 1 and 5, produced IL-1RA expression
similar to or reduced from negative control.
No THP-1 cells exposed to suture expressed CD163
on day one. Perma-Hand® caused the highest increase in
CD163 expression, compared to negative control, on day
3 with a statistically significant 43-fold increase (p <
0.0001), compared to negative control. This suture also
caused a significant 11-fold increase in CD163 expres-
sion on day 5 (p < 0.05). Moreover, CD163 was signifi-
cantly upregulated 14-fold by exposure to VICRYL® on
day 3 (p < 0.01). Ethilon® and Ti-Cron® had increased
CD163 expression on days 3 and 5, as well as FiberWire®
on day 5, however, these did not reach statistical signifi-
cance. MONOCRYL® and Ethibond EXCEL® produced
similar levels of CD163 expression to negative control
across the culture period.
IL-1β/IL-1RA ratio
A pro-/anti-inflammatory marker ratio was produced for
all sutures by dividing the value for fold-increase in
IL-1β gene expression, by the value for fold-increase
in IL-1RA gene expression, the inhibitor of IL-1β, over
all time points (Fig. 2). This was done to predict the
balance of pro- and anti-inflammatory expression elicited
in macrophage cells exposed to the suture materials.
Compared to negative control, VICRYL® and Perma-Hand®
achieve a ratio skewed towards pro-inflammation on days 1
and 3, with values of 2.5 and 8.5, and 2.7 and 4.5, respect-
ively. The Ti-Cron® suture favoured pro-inflammation on
days 3 and 5 with ratios of 3 and 10 respectively. FiberWire®
produced a propensity for pro-inflammation on day 5,
with a ratio of 11.5. MONOCRYL®, Ethilon® and Ethibond
EXCEL® produced similar IL-1β:IL-1RA ratios to negative
control over all time points.
Protein secretion analysis
The concentration of IL-1β protein released by THP-1
cells into media, in response to culture with the suture
materials, was measured using ELISA on days 1, 3 and
5. Means from three combined independent biological
experiments are reported (Fig. 3).
LPS upregulated IL-1β secretion over the entire cul-
ture period, however, was only statistically significant
on day 5 (p < 0.05). IL-1β protein secretion matched the
IL-1β gene expression data with peak secretion levels
coming on day 3 for all suture materials. Of all suture
materials, exposure to Perma-Hand® produced the greatest
increase in IL-1β secretion over negative control, with 60
and 48pg/ml secretion on days 3 and 5, respectively. The
next highest increase came from THP-1 cells in contact
with VICRYL® on days 3 and 5, with 50 and 38pg/ml, re-
spectively. Ti-Cron® also upregulated IL-1β on day 3 with
16pg/ml secretion. However, none of these reached statis-
tical significance. All other sutures had IL-1β secretion
levels similar to, or reduced below negative control values
across the culture period.
Discussion
This is the first comprehensive study directly comparing
immune response of suture materials, in vitro. The findings
from our in vitro study suggest that VICRYL®, Ti-Cron®,
FiberWire® and Perma-Hand® suture materials cause upreg-
ulation of pro-inflammatory marker genes early in the
Fig. 2 Pro-/Anti-Inflammatory Marker Ratio. A pro-/anti-inflammatory marker ratio was produced for all sutures, by dividing the value for fold-increase
in IL-1β gene expression, by the value for fold-increase in IL-1RA gene expression, over all time points
Lock et al. Patient Safety in Surgery  (2017) 11:16 Page 5 of 8
foreign body reaction, while MONOCRYL®, Ethilon® and
Ethibond EXCEL® sutures remain reasonably inert. Pro-/
anti-inflammatory ratios convey no balancing from anti-
inflammatory marker genes and protein secretion analysis
matched gene expression data for IL-1β over the culture
period.
The term foreign body reaction describes the body’s
inflammatory reaction to foreign objects, such as suture
materials. The action of introducing a suture material
for wound closure in a living host causes insult, releasing
activational cytokines and initiating a chain of inflamma-
tion. There are two main macrophage sub-types which
play a central and critical role in wound healing at the
foreign body site, M1 (classically activated) and M2
(alternatively activated) [16].
The M1 sub-type is characterised by the release of
large amounts of pro-inflammatory cytokines, including
IL-1β, IL-1α, IL-6, IL-8, IL-12 and TNFα, and by surface
marker expression, principally CCR7. The M1 lineage
functions in pro-local and systemic inflammation, and if
persistent around sites of suture deposition, result in less
than optimal wound healing [15, 16]. The M2 sub-type
has three independent types, of which the M2c type is
the most relevant for suture site repair. Conversely, these
macrophages are known to promote wound healing, re-
modelling and extracellular matrix deposition, by releasing
large amounts of anti-inflammatory cytokines such as
TGFβ, IL-1RA and IL-10. M2c macrophages can also be
characterised by surface marker expression, principally
CD163 and cluster of differentiation 206 (CD206) [15, 16].
In this study, relative gene expression of six inflammatory
cytokines (IL-1β, IL-1α, TNFα, IL-8, TGFβ1 and IL-RA)
and two cell surface markers (CCR7 and CD163) were
measured in vitro to assess immune compatibility for seven
surgical suture materials. These markers were chosen
because they represented a combination of both M1
and M2c markers, allowing assessment of both pro-/
anti-inflammatory response to the suture materials.
Moreover, their detection has consistently been shown
in previous literature assessing immune response to
other biomaterials [15, 17–19]. A balance was chosen
such that measuring additional markers would be neither
economical nor likely to add further information.
Here, we present an in vitro co-incubation model of
different suture materials with the human monocyte/
macrophage cell line, THP-1. THP-1 cells are homogenous
monocytic cells, developed from the peripheral blood of a
one-year old infant with acute monocytic leukaemia, that
can be activated into mature macrophage cells in vitro [20].
As an immortalized cell line, that can grow and divide in-
definitely in vitro, there are certain limitations regarding
the conclusions that can be drawn in relation to in vivo
monocyte/macrophage response. However, a recent study
compared the ability of THP-1 cells to mimic monocytes/
macrophages, and determined that, along with the low vari-
ability and higher reproducibility of a cell line, under certain
conditions, THP-1 cells are capable of resembling primary
monocyte/macrophages isolated from healthy patients [21].
Seven suture materials used in general soft tissue
approximation were assessed for in vitro immune re-
sponse. VICRYL® and MONOCRYL® are absorbable
sutures which remain inside the body, and are broken
down over many months following implantation. VICRYL®
is a synthetic copolymer composed of 90% glycolide and
10% L-lactide, while MONOCRYL® is a monofilament
synthetic copolymer of glycolide and epsilon-caprolactone
[22]. The remaining five suture materials are non-ab-
sorbable, meaning they must be removed after enough
time has passed to allow sufficient wound healing. Usually,
this time period is at least 10 days duration [22]. These su-
tures were Ethilon®, a monofilament suture composed of
the long chain aliphatic polymers Nylon 6 and Nylon 6,6
[22], Ti-Cron®, a suture composed of polyethylene tereph-
thalate with a silicone coating [7], FiberWire®, composed
of a braided polyester jacket with a polyethylene core [8],
Perma-Hand®, a silk suture composed of an organic fi-
broin protein derived from the Bombyx mori silkworm
[23], and finally, Ethibond EXCEL®, a suture composed
Fig. 3 Protein Secretion Results. The concentration of IL-1β protein released by THP-1 cells into media, in response to culture with the suture
materials, was measured using ELISA on days 1, 3 and 5. Means from three independent biological repeats is reported ± SEM. Statistical analysis
was performed using two-way ANOVA and post-hoc Dunnett’s test (*p < 0.05)
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of braided polyethylene terephthalate, with a polybuti-
late coat [22].
Our gene expression results suggest that VICRYL®,
Ti-Cron®, FiberWire® and Perma-Hand® suture materials
cause upregulation of pro-inflammatory markers early in
the foreign body reaction, with no balancing from anti-
inflammatory markers. In fact, all anti-inflammatory
markers measured were expressed at much lower levels
compared with their pro-inflammatory counterparts, and
this observation was reflected in the increased IL-1β/IL-
1RA ratio for VICRYL®, Ti-Cron®, FiberWire® and Perma-
Hand®. The protein secretion results matched this gene
data for IL-1β expression over the culture period, adding
the validity of translational data with transcriptional.
Pro-inflammation seemed to peak on day three of cul-
ture for most markers assessed, however, several of the
pro-inflammatory markers persisted to be high in an
absolute sense on day five of culture. Prolonged pro-
inflammation, with no subsequent anti-inflammatory peak,
is known to produce delayed wound healing responses
[24–26]. Such early unbalanced immune reactions can
jeopardise success of healing, and this has been shown
both with cutaneous wound healing and in models of bony
non-union [27–29]. Certainly, persistent pro-inflammation
would be expected to hinder wound healing around suture
implant sites as well. The three other sutures tested,
MONOCRYL®, Ethilon® and Ethibond EXCEL®, remained
reasonably inert over the entire culture period.
The IL-1β/IL-1RA ratio used in this study was calcu-
lated as a simple measure of whether inflammation was
skewed more toward an M1 or M2c type of macrophage
response. This ratio supplements the absolute data for
pro-/anti-inflammatory cytokine expression. A disadvan-
tage of using this ratio is that absolute changes in indi-
vidual cytokine expression on either side of the ratio,
might not represent biologically equal impact [30, 31].
Using multiple M1 and M2c markers when creating the
ratio may reduce some error from this, although meas-
uring protein secretion data may be more reliable.
The authors could see no clear commonality between
the four sutures which would suggest a reason for the
increased pro-inflammatory responses. Furthermore, we
feel it is not possible to rank those sutures in order of
response, as each increased different pro-inflammatory
cytokines to varying degrees. However, we feel this study
does provide useful data towards the options surgeons
have, when choosing between various absorbable and
non-absorbable suture varieties required in wound closure.
Our data would suggest that, if a surgeon requires an
absorbable suture, then MONOCRYL® would produce less
inflammatory response compared with VICRYL®. Moreover,
Ethilon® and Ethibond EXCEL® sutures would produce less
inflammation compared with Ti-Cron®, FiberWire® and
Perma-Hand®. A reduced inflammatory response would
expectantly produce better wound healing and wound
closure, with less chance of SRPI and granuloma
formation.
In vivo literature is available for some of these sutures,
amongst others, with comparable results to our in vitro
assessment. Carr et al. (2009) evaluated 8 common sutures
(Ethibond EXCEL®, Ti-Cron®, HiFi®, Ultrabraid®, MaxBraid®,
Orthocord®, MagnumWire® and FiberWire®) in a rabbit
model and graded them up to 120 days post implant, con-
cluding MagnumWire® and Ti-Cron® to stimulate the most
intense inflammatory responses [5]. Other studies have
been undertaken in rats. Molea et al. (2000) evaluated three
bioresorbable monofilament sutures (PDS II®, MONO-
CRYL® and Biosyn®) up to 6 months post-implantation [32].
Despite all three materials being accepted, PDS II® suture
showed an increased histological inflammatory reaction.
Other rat studies have evaluated PDS II®, MONOCRYL®,
VICRYL®, Chromic Gut® and e-PTFE®. Despite acceptance
from the animals, VICRYL® suture showed the highest level
of inflammation on histological evaluation [33, 34].
Although in vivo studies have often been deemed the
gold standard for assessing immune response, here we
have demonstrated in vitro techniques with the sensitivity
to distinguish between materials likely to induce a foreign
body response, and those unlikely to, and these results
largely mirror the previous in vivo studies [5, 32–34].
Given that there is a large global push for a reduction in
experimental animal usage [11], we feel that similar in
vitro testing is a viable, and ethically friendly option that
could be further utilised to evaluate materials used in sur-
gery, such as other suture materials and suture anchors.
This would provide surgeons with the information re-
quired to make informed surgical decisions, and ultim-
ately improve patient safety.
Conclusions
Our findings suggest that VICRYL®, Ti-Cron®, FiberWire®
and Perma-Hand® suture materials cause the upregula-
tion of pro-inflammatory cytokines indicative of early
foreign body reaction. This work has the potential to not
only reduce suture-related adverse immune reactions,
but the increased knowledge produced from this work
will improve informed surgical decision making and ul-
timately enhance patient safety.
Abbreviations
ANOVA: Analysis of variance; CCR7: C-C chemokine receptor Type 7;
CD163: Cluster of differentiation 163; CD206: Cluster of differentiation 206;
ELISA: Enzyme-linked immunosorbent assay; IL-10: Interleukin-10; IL-
12: Interleukin-12; IL-1RA: Interleukin-1 receptor antagonist; IL-1α: Interleukin-1
alpha; IL-1β: Interleukin-1 beta; IL-6: Interleukin-6; IL-8: Interleukin-8;
LPS: Lipopolysaccharide; M1: Classically activated macrophage sub-type
(Pro-inflammatory); M2: Alternatively activated macrophage sub-type;
M2c: Type of alternatively activated macrophages (Anti-inflammatory);
qPCR: Quantitative polymerase chain reaction; RPMI: Roswell park memorial
institute; SRPI: Suture-related pseudoinfection; TGFβ: Transforming growth
factor beta; TNFα: Tumour necrosis factor alpha
Lock et al. Patient Safety in Surgery  (2017) 11:16 Page 7 of 8
Acknowledgments
The authors would like to thank Ms Ally Choi and Mrs Karen E Callon for
their education of laboratory protocol for equipment used in this study.
Funding
This work was part funded by the Health Research Council of New Zealand
(15/576), the New Zealand Orthopaedic Association, the Wishbone Trust and
supported by the European Union Seventh Framework Programme skelGEN
(FP7/2007–2013) under grant agreement n° [318553]. The funders took no
part in the analyses nor the writing of this manuscript.
Availability of data and materials
The datasets used and/or analysed during the current study available from
the corresponding author on reasonable request.
Authors’ contributions
Design of study protocol: BC, JC, DN and DM. Collection of samples: RG, BC.
Acquisition of study data: AL and DM. Data analysis: AL, DN and DM.
Interpretation of data: AL, RG, DN BC, JC and DM. Drafting of manuscript: AL
and DM. Final approval of manuscript: all authors.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Medicine, University of Auckland, Private Bag 92019,
Auckland 1142, New Zealand. 2Department of Orthopaedics, Middlemore
Hospital, Private Bag 93311, Auckland, New Zealand.
Received: 3 February 2017 Accepted: 22 May 2017
References
1. Salthouse TN, Matlaga BF, Wykoff MH. Comparative tissue response to six
suture materials in rabbit cornea, sclera, and ocular muscle. Am J
Ophthalmol. 1977;84(2):224–33.
2. Salthouse TN. Biologic response to sutures. Otolaryngol Head Neck Surg.
1980;88(6):658–64.
3. Altman GH, Diaz F, Jakuba C, Calabro T, Horan RL, Chen J, Lu H, Richmond
J, Kaplan DL. Silk-based biomaterials. Biomaterials. 2003;24(3):401–16.
4. Meinel L, Hofmann S, Karageorgiou V, Kirker-Head C, McCool J, Gronowicz
G, Zichner L, Langer R, Vunjak-Novakovic G, Kaplan DL. The inflammatory
responses to silk films in vitro and in vivo. Biomaterials. 2005;26(2):147–55.
5. Carr BJ, Ochoa L, Rankin D, Owens LBD. Biologic response to orthopedic
sutures: a histologic study in a rabbit model. Orthopedics. 2009;32(11):828.
6. Smith TO, Sexton D, Mann C, Donell S. Sutures versus staples for skin
closure in orthopaedic surgery: meta-analysis. BMJ. 2010;340:c1199.
7. Warme WJ, Burroughs RF, Ferguson T. Late foreign-body reaction to ticron
sutures following inferior capsular shift: a case report. Am J Sports Med.
2004;32(1):232–6.
8. Mack AW, Freedman BA, Shawen SB, Gajewski DA, Kalasinsky VF, Lewin-
Smith MR. Wound complications following the use of FiberWire in lower-
extremity traumatic amputations. JBJS Case Connector. 2009;91(3):680–5.
9. Sayegh S, Bernard L, Stern R, Pache J, Szalay I, Hoffmeyer P. Suture
granuloma mimicking infection following total Hip arthroplasty. JBJS Case
Connector. 2003;85(10):2006–9.
10. Pierannunzii L, Fossali A, De Lucia O, Guarino A. Suture-related pseudoinfection
after total hip arthroplasty. J Orthop Traumatol. 2015;16(1):59–65.
11. Flecknell P. Replacement, reduction and refinement. ALTEX. 2002;19(2):73–8.
12. Uff CR, Scott AD, Pockley AG, Phillips RK. Influence of soluble suture factors
on in vitro macrophage function. Biomaterials. 1995;16(5):355–60.
13. Musson DS, Naot D, Chhana A, Matthews BG, McIntosh JD, Lin ST, Choi AJ,
Callon KE, Dunbar PR, Lesage S. In vitro evaluation of a novel non-mulberry
silk scaffold for use in tendon regeneration. Tissue Eng A. 2015;21(9–10):
1539–51.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2− ΔΔCT method. Methods. 2001;25(4):
402–8.
15. Franz S, Rammelt S, Scharnweber D, Simon JC. Immune responses to
implants–a review of the implications for the design of immunomodulatory
biomaterials. Biomaterials. 2011;32(28):6692–709.
16. Anderson JM, McNally AK. Biocompatibility of implants: lymphocyte/
macrophage interactions. Semin Immunopathol. 2011;33:221–33.
17. Bryers JD, Giachelli CM, Ratner BD. Engineering biomaterials to integrate
and heal: the biocompatibility paradigm shifts. Biotechnol Bioeng. 2012;
109(8):1898–911.
18. Jones JA, Chang DT, Meyerson H, Colton E, Kwon IK, Matsuda T, Anderson
JM. Proteomic analysis and quantification of cytokines and chemokines
from biomaterial surface‐adherent macrophages and foreign body giant
cells. J Biomed Mater Res A. 2007;83(3):585–96.
19. Chang DT, Jones JA, Meyerson H, Colton E, Kwon IK, Matsuda T, Anderson
JM. Lymphocyte/macrophage interactions: biomaterial surface‐dependent
cytokine, chemokine, and matrix protein production. J Biomed Mater Res A.
2008;87(3):676–87.
20. Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH. The
identification of markers of macrophage differentiation in PMA-stimulated
THP-1 cells and monocyte-derived macrophages. PLoS One. 2010;5(1):e8668.
21. Qin Z. The use of THP-1 cells as a model for mimicking the function and
regulation of monocytes and macrophages in the vasculature.
Atherosclerosis. 2012;221(1):2–11.
22. Tajirian AL, Goldberg DJ. A review of sutures and other skin closure
materials. Journal of Cosmetic and Laser Therapy. 2010;12(6):296–302.
23. Yaltirik M, Dedeoglu K, Bilgic B, Koray M, Ersev H, Issever H, Dulger O, Soley
S. Comparison of four different suture materials in soft tissues of rats. Oral
Dis. 2003;9(6):284–6.
24. Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic
and delayed healing. Front Biosci. 2004;9(1):283–9.
25. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic‐Canic M. Growth
factors and cytokines in wound healing. Wound Repair Regen. 2008;16(5):
585–601.
26. Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res. 2010;89(3):
219–29.
27. Fivenson DP, Faria DT, Nickoloff BJ, Poverini PJ, Kunkel S, Burdick M, Strieter
RM. Chemokine and inflammatory cytokine changes during chronic wound
healing. Wound Repair Regen. 1997;5(4):310–22.
28. Stadelmann WK, Digenis AG, Tobin GR. Physiology and healing dynamics of
chronic cutaneous wounds. Am J Surg. 1998;176(2):26S–38S.
29. Schmidt‐Bleek K, Schell H, Lienau J, Schulz N, Hoff P, Pfaff M, Schmidt G,
Martin C, Perka C, Buttgereit F. Initial immune reaction and angiogenesis in
bone healing. J Tissue Eng Regen Med. 2014;8(2):120–30.
30. Badylak SF, Valentin JE, Ravindra AK, McCabe GP, Stewart-Akers AM.
Macrophage phenotype as a determinant of biologic scaffold remodeling.
Tissue Eng A. 2008;14(11):1835–42.
31. Fujisaka S, Usui I, Bukhari A, Ikutani M, Oya T, Kanatani Y, Tsuneyama K,
Nagai Y, Takatsu K, Urakaze M, Kobayashi M, Tobe K. Regulatory
mechanisms for adipose tissue M1 and M2 macrophages in diet-induced
obese mice. Diabetes. 2009;58(11):2574–82.
32. Molea G, Schonauer F, Bifulco G, D’Angelo D. Comparative study on
biocompatibility and absorption times of three absorbable monofilament
suture materials (polydioxanone, poliglecaprone 25, glycomer 631). Br J
Plast Surg. 2000;53(2):137–41.
33. Nary Filho H, Matsumoto MA, Batista AC, Lopes LC. Sampaio góes, fernanda
Costa grizzo de, consolaro a. Comparative study of tissue response to
polyglecaprone 25, polyglactin 910 and polytetrafluorethylene suture
materials in rats. Braz Dent J. 2002;13(2):86–91.
34. Andrade MG, Weissman R, Reis SR. Tissue reaction and surface morphology
of absorbable sutures after in vivo exposure. J Mater Sci Mater Med. 2006;
17(10):949–61.
Lock et al. Patient Safety in Surgery  (2017) 11:16 Page 8 of 8
